Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary aldosteronism: state-of-the-art review. Am J Hypertens. 2022;35:967–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang MH, Tyan YS, Huang YH, Wang SC, Chen SL. Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma. Radio Med. 2016;121:811–9.

Article  Google Scholar 

Inoue H, Nakajo M, Miyazono N, Hori A, Kanetsuki I, Hokotate H, et al. Successful therapeutic embolization of aldosteronoma using absolute ethanol. Radiat Med. 1993;11:256–9.

CAS  PubMed  Google Scholar 

Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial. J Clin Hypertens. 2020;22:1618–26.

Article  Google Scholar 

Dong H, Zou Y, He J, Deng Y, Chen Y, Song L, et al. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheter Cardiovasc Inter. 2021;97:976–81.

Article  Google Scholar 

Zhou Y, Liu Q, Wang X, Wan J, Liu S, Luo T, et al. Adrenal ablation versus mineralocorticoid receptor antagonism for the treatment of primary aldosteronism: a single-center prospective cohort study. Am J Hypertens. 2022;35:1014–23.

Article  CAS  PubMed  Google Scholar 

Qiu J, Li N, Xiong HL, Yang J, Li YD, Hu CK, et al. Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion: an efficacy and safety, proof-of-principle study. Hypertens Res. 2023;46:1297–310.

Article  CAS  PubMed  Google Scholar 

Lai ZQ, Fu Y, Liu JW, Zhang HJ, Zhang H, Liang NP, et al. The impact of superselective adrenal artery embolization on renal function in patients with primary aldosteronism: a prospective cohort study. Hypertens Res. 2023; https://doi.org/10.1038/s41440-023-01503-8.

Kobayashi H, Abe M, Nakamura Y, Takahashi K, Fujita M, Takeda Y, et al. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension. 2019;74:630–8.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Wang X, Hou J, Wan J, Yang Y, Liu S, et al. A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism. Hypertens Res. 2023; https://doi.org/10.1038/s41440-023-01420-w.